超预期创新药BD带动医药板块共振

Group 1 - Huatai Securities reports that the Hong Kong innovative drug sector has seen significant liquidity recovery since the beginning of 2026, with BD transactions exceeding expectations compared to the same period last year [1] - The report anticipates a clear innovative drug beta market driven by liquidity recovery, with expectations for breakthroughs beyond previous highs [1] - External demand-driven CXO performance continues to exceed expectations, likely resonating with the innovative drug sector [1] Group 2 - CITIC Construction Investment indicates that the global interest rate cut cycle is entering its second half in 2026, characterized by "internal and external easing resonance" and a shift from abnormal to normal conditions [2] - The report highlights that the depreciation of the US dollar and appreciation of the RMB support a strong A-share market [2] - The "stock-bond seesaw" effect is expected to further support A-share performance, with a notable increase in demand for reallocation of household deposits [2] Group 3 - China Merchants Securities states that the slight recovery of sow production capacity in 2024 will lead to a downward trend in pig prices in 2025, although there may still be slight profits for the year [3] - The industry is experiencing both passive and active capacity reduction due to price drops below cash costs, with sow production capacity entering an accelerated reduction phase from October [3] - The report predicts a gradual recovery in pig prices in the second half of 2026, with quality pig enterprises continuing to expand their cost advantages and improve cash flow [3]